please refer attachment

Revenue DeclinePat Growth 25pctEbitda Margin CompressionNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.2%1-day move

₹26.25

prior close

₹26.77

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.3+0.2+0.2+2.2+2.8+1.7-2.9+0.6-3.8-1.6-1.0-2.2—

Up moveDown movePending

AI summary

Emmessar Biotech & Nutrition Ltd reported audited standalone financial results for the year ended 31 March 2026. Total income declined to ₹240.66 lakhs from ₹261.96 lakhs in the prior year, a fall of about 8%. Revenue from operations (Healthcare segment) dropped sharply from ₹61.09 lakhs to ₹37.08 lakhs, though this was partially offset by stable rent income of ₹165.31 lakhs. Despite lower PBT of ₹57.96 lakhs (vs ₹95.82 lakhs), net profit after tax grew 37.8% to ₹43.59 lakhs due to a significant reduction in tax expense from ₹64.20 lakhs to ₹14.37 lakhs. The company operates in two segments: Healthcare and Rent on leasehold land. No exceptional items were reported. The auditors V. Nagarajan & Co. issued an unmodified (clean) opinion on the financial results.

Likely market impact

The stock may see mixed reaction: PAT growth is positive but revenue decline and EBITDA margin compression (from ~40% to ~28%) signal weakening core business performance. The clean audit opinion is reassuring for governance-conscious investors.